Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Accendra Health, Inc.NYSE: ACH
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $51.08M fell 44.9% year over year, behind the +164.2% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -49.9% a year.
Context
- Financing cash flow amounted to 6.8% of revenue in FY2025, up 4.3 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -44.9% toward the trailing-twelve-month pace of +164.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 188.08M USD
- Year-over-year change
- +170.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 188.08M | +170.3% |
| FY2024 | 2024-12-31 | (267.6M) | +35.9% |
| FY2023 | 2023-12-31 | (417.33M) | -127.9% |
| FY2022 | 2022-12-31 | 1.5B | +1256.3% |
| FY2021 | 2021-12-31 | (129.48M) | — |
Financing Cash Flow vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +164.2% is the 2nd highest of 11, against a peer median of -32.6%.
- Financing cash flow amounts to 5.4% of revenue for ACH, versus a peer median of 62.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$366.4M CAD | +146.5% | — | 117.3% | |
| LTM Mar 2026 | $146.38M USD | +164.2% | -49.9% | 5.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $136.68M USD | -35.4% | +66.2% | 1325.0% |
| LTM Mar 2026 | $126.17M USD | +2854.7% | +44.9% | — | |
| LTM Mar 2026 | $52.19M USD | -29.8% | — | 623.8% | |
| LTM Mar 2026 | $41.91M USD | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $37.29M USD | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $9.79M USD | -84.7% | +12.0% | 16.6% | |
| LTM Mar 2026 | $1.86M USD | -68.5% | +12.8% | 2.3% | |
| LTM Apr 2026 | CA$608.92K CAD | +104.3% | -76.3% | 0.1% | |
| LTM Mar 2026 | $348K USD | -99.4% | -8.7% | 0.3% | |
| Peer median (excluding ACH) | — | -32.6% | +28.8% | 62.4% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (102.68M) |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| Deferred Income Tax | (29.74M) | (26.36M) | (23.65M) | (26.12M) | (17.89M) |
| Stock-Based Compensation | 25.02M | 20.99M | 23.22M | 26.84M | 12.87M |
| Change in Working Capital | (261.4M) | 89.77M | 522.29M | (25.44M) | 65.21M |
| Accounts Receivables | (2.2M) | 1.1M | 166.58M | (94.55M) | 122.36M |
| Inventory | (263.44M) | 166.56M | 224.34M | (26.23M) | (6.85M) |
| Accounts Payables | 3.55M | 13.65M | 31M | 65.19M | 6.48M |
| Other Working Capital | 692K | (91.54M) | 100.37M | 30.15M | (56.78M) |
| Other Non-Cash Items | 78.09M | (10.45M) | (27.22M) | 284.12M | (273.83M) |
| Operating Cash Flow | 124.18M | 325.01M | 740.71M | 161.5M | (101.79M) |
| Capital Expenditures | (49.69M) | (166.58M) | (207.89M) | (228.16M) | (201.33M) |
| Acquisitions (Net) | (43.37M) | (1.68B) | 0 | 0 | 324.26M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 39.43M | 46.71M | 53.62M | 94.33M | 11.12M |
| Investing Cash Flow | (53.63M) | (1.8B) | (137.25M) | (116.53M) | 144.42M |
| Debt Repayment | (95.35M) | 1.58B | (416.69M) | (244.2M) | 203.5M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (10.18M) |
| Dividends Paid | (731K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (33.4M) | (85.4M) | (637K) | (23.41M) | (5.24M) |
| Financing Cash Flow | (129.48M) | 1.5B | (417.33M) | (267.6M) | 188.08M |
| Effect of Forex Changes | (3.54M) | (3.49M) | 613K | (901K) | 1.9M |
| Net Change in Cash | (62.47M) | 14.15M | 186.74M | (223.54M) | 232.61M |
| Free Cash Flow | 74.49M | 158.42M | 532.82M | (66.67M) | (303.12M) |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.